Search results
Results from the WOW.Com Content Network
As of 2021, India's APIs market is worth $11.8 billion and is forecasted to grow at a compound annual growth rate of 12.24% until 2027. [35] Several Indian companies manufacture APIs. One of India's largest pharmaceutical companies, Divi's Laboratories, is the world's largest manufacturer of more than 10 generic APIs. [36]
Panacea Biotec is a global generic and specialty pharmaceutical and vaccine maker. It has principal offices in New Delhi, Mumbai, and Lalru (near Chandigarh). It has business interests in research, development, manufacturing and marketing of pharmaceutical formulations, vaccines, biosimilars, and natural products. [1]
ACG is a multinational pharmaceutical company with headquarters in Mumbai, India.The company has presence in over 100 countries on six continents. [1] ACG is the world’s largest integrated supplier of solid dosage products and services. [2]
Upgrade to a faster, more secure version of a supported browser. It's free and it only takes a few moments:
Emcure Pharmaceuticals was established in 1981 by Satish Mehta, who began the company with a bank loan of ₹ 3 lakh (about US$35,000 then) after graduating from IIM-A. [9] In the 1990s, the company transitioned from being a contract manufacturing organization to a producer of generic drugs .
Lupin is the fastest-growing Top 10 generic pharmaceuticals player in Japan (IMS) [citation needed]. It operates in Japan through its subsidiary, Kyowa Pharmaceutical Industry Co. Ltd. (Kyowa), a company acquired in 2007, [29] [30] and I’rom, Pharmaceutical Co. Ltd (IP), acquired in 2011.
Regulatory developments, FDA/EMEA news, market legislation, pharma market movements, reviews of current and proposed legislation and regulation, conference details, and write-ups. Barbara Obstoj is the Managing Editor, which in 2009 acquired the archives of The Pharma Marketletter, a publication Barbara owned since 1991 and prior to that edited ...
The United States has 81,000 pharmaceutical representatives or 1 for every 7.9 physicians. [2] The number and persistence of pharmaceutical representatives has placed a burden on the time of physicians. [9] "As the number of reps went up, the amount of time an average rep spent with doctors went down—so far down, that tactical scaling has ...